Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases

Springer Science and Business Media LLC - Tập 41 - Trang 2397-2404 - 2023
Stefanie Latarius1, Steffen Leike1, Holger Erb1, Juliane Putz1, Angelika Borkowetz1, Christian Thomas1, Martin Baunacke1
1Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany

Tóm tắt

Retroperitoneal lymph node dissection (RPLND) for germ cell tumours is a challenging procedure that may present relevant complications. The purpose was to analyse postoperative complications and identify risk factors for major complications. This is a retrospective unicentric analysis of a large cohort of 295 RPLNDs from 1992 to 2020. Early complications (30 days) and late complications (31–180 days) were classified according to the Clavien‒Dindo classification. The influence of surgical, patient-specific, and tumour-specific parameters on grade III–V complications was analysed in univariate and multivariate logistic regression models. A total of 232 were postchemotherapy RPLNDs, and 63 were primary RPLNDs. Early postoperative complications were found to be grades I–II in 58.6% (173/295), grades III–IV in 9.8% (29/295), and grade V in 0.3% (1/295). In 20% (58/295), additional surgical procedures were needed. Grade III–V complications were associated with ≥ 4 cycles of preoperative chemotherapy (OR 3.7 (1.5–8.9); p = 0.004), RPLND specimen (nonseminoma or immature teratoma) (OR 3.1 (1.4–6.6); p = 0.005), transfusions (OR 2.4 (1.1–5.4); p = 0.03), salvage RPLND (OR 4.1 (1.8–9.3); p < 0.001), and preoperatively elevated AFP (OR 5 (2.2–11.7); p < 0.001). In multivariate analysis, the only independent predictor for grade III–V complications was preoperative AFP elevation (OR 3.3 (1.2–9.2); p = 0.02). Limitations include the retrospective study design. Our results demonstrate that RPLND is a demanding surgical procedure. Patients with a complex tumour history have a higher risk of complications. We recommend treatment of these complex cases in high-volume centres.

Tài liệu tham khảo

Park JS, Kim J, Elghiaty A, Ham WS (2018) Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 97(37):e12390

Beyer J, Collette L, Sauve N, Daugaard G, Feldman DR, Tandstad T et al (2021) Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol 39(14):1553–1562

Dieckmann KP, Anheuser P, Kulejewski M, Gehrckens R, Feyerabend B (2018) Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study. BMC Urol 18(1):95

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068

Tanaka T, Kitamura H, Kunishima Y, Takahashi S, Takahashi A, Masumori N et al (2006) Modified and bilateral retroperitoneal lymph node dissection for testicular cancer: peri- and postoperative complications and therapeutic outcome. Jpn J Clin Oncol 36(6):381–386

Cary C, Masterson TA, Bihrle R, Foster RS (2015) Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. Urol Oncol 33(9):389 e15–e21

Ruf CG, Krampe S, Matthies C, Anheuser P, Nestler T, Simon J et al (2020) Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature. World J Surg Oncol 18(1):253

Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169(6):2126–2128

Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D (2017) Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol 28(2):362–367

Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J (2007) Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 25(9):1033–1037

Yu HY, Hevelone ND, Patel S, Lipsitz SR, Hu JC (2012) Hospital surgical volume, utilization, costs and outcomes of retroperitoneal lymph node dissection for testis cancer. Adv Urol 2012:189823

Groeben C, Koch R, Nestler T, Kraywinkel K, Borkowetz A, Wenzel S et al (2020) Centralization tendencies of retroperitoneal lymph node dissection for testicular cancer in Germany? A total population-based analysis from 2006 to 2015. World J Urol 38(7):1765–1772

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213

Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M et al (2012) Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol 61(2):341–349

Gerdtsson A, Hakansson U, Tornblom M, Jancke G, Negaard HFS, Glimelius I et al (2020) Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the swedish norwegian testicular cancer group. Eur Urol Oncol 3(3):382–389

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196

Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG et al (2006) Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483–1490

Flum AS, Bachrach L, Jovanovic BD, Helenowski IB, Flury SC, Meeks JJ (2014) Patterns of performance of retroperitoneal lymph node dissections by American urologists: most retroperitoneal lymph node dissections in the United States are performed by low-volume surgeons. Urology 84(6):1325–1328

Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A et al (2022) Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol 40(6):1505–1512

Lloyd P, Hong A, Furrer MA, Lee EWY, Dev HS, Coret MH et al (2022) A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World J Urol 40(1):119–126

Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA (2010) Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 28(5):504–509

Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP (2010) Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int 106(6):779–785

Hiester A, Nini A, Fingerhut A, Grosse Siemer R, Winter C, Albers P et al (2018) Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in patients with testicular cancer: template vs. bilateral resection. Front Surg 5:80

Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W et al (2010) Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol 8:97

Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169(5):1710–1714

Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA et al (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94(6):1668–1676

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22(6):1034–1039

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 41

2397-2404

Thông tin tác giả